Cystatin C (Cys-C), an alternative to renal markers like creatinine and glomerular filtration rate, can effectively predict a patient’s risk for adverse CVD events after an acute coronary syndrome (ACS), researchers reported Oct. 12 in the Journal of the American Heart Association.

A study presented at TCT 2018 questioned the benefits of “drip-and-ship” for elderly patients with ST-segment elevation myocardial infarction (STEMI), finding patients in their 80s or older who were transferred with fibrinolytic therapy for PCI had an eight-fold risk of hemorrhagic stroke but no survival advantage.

Fewer than one-third of Chinese patients with acute coronary syndromes (ACS) receive guidance to participate in cardiac rehabilitation, according to research presented Oct. 11 at the Great Wall International Congress of Cardiology.

People with unrecognized myocardial infarction carry a lower short-term risk of death but an equal 10-year risk of mortality compared to those with clinically diagnosed heart attacks, according to an analysis of the ICELAND MI study published in JAMA Cardiology.

A genomic risk prediction tool developed by researchers in Australia and the U.K. has achieved greater risk discrimination than its predecessors while identifying patients at the highest and lowest likelihood of developing coronary artery disease (CAD), according to a study published ahead of print in the Journal of the American College of Cardiology.

Cardiovascular risk factors have similar effects on the incidence of coronary heart disease (CHD) and ischemic stroke in women, researchers report in the first large-scale study of its kind in female patients.

Though they might provide some benefit to high-risk patients in the month after a heart attack, wearable cardioverter-defibrillators don’t significantly lower the rate of arrhythmic death in those who have suffered myocardial infarctions, according to work published in the New England Journal of Medicine Sept. 27.

Cardiologists at Henry Ford Hospital in Detroit have successfully performed the country’s first implantation of the Neovasc Reducer—a stainless steel, hourglass-shaped heart mesh designed to alleviate difficult angina—the hospital announced in a statement Sept. 26.